Sagimet Biosciences Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Sagimet is a clinical-stage biopharmaceutical company developing fatty acid synthase inhibitors; it has no approved products and reported no revenue for the quarter.
Financial performance and liquidity
- Revenue: $0 recognized in Q1 2024 and Q1 2023. The company has not generated product-sales revenue.
- Expenses and loss: R&D expense was $5.3 million, up 17% year over year; G&A was $3.5 million, up 54%. Total operating expenses were $8.8 million, and operating loss was $8.8 million. Net loss was $6.6 million, versus $6.6 million a year earlier.
- Other income: $2.1 million, primarily interest income on cash and investments, compared with $0.2 million in Q1 2023.
- Margins: Not meaningful because the company reported no revenue.
- Cash flow: $6.2 million used in operating activities; $3.0 million provided by sales of marketable securities; and $104.8 million provided by financing activities, principally the January follow-on offering. Cash and cash equivalents rose by $101.6 million during the quarter.
- Liquidity: Cash and cash equivalents were $176.8 million and marketable securities were $16.9 million at March 31, 2024, totaling $193.7 million. Management expects these resources to fund operating and capital requirements for at least 12 months from issuance of the statements.
- Debt and liabilities: The balance sheet reports total liabilities of $4.5 million; no borrowings are listed. The company has an accumulated deficit of $256.4 million and expects further losses and negative operating cash flows.
Changes versus the prior-year quarter
- Operating expenses increased 30%, reflecting higher clinical manufacturing and other research costs, and higher personnel, insurance, corporate-tax and public-company compliance costs.
- R&D increased $0.8 million: a $1.6 million rise in denifanstat clinical manufacturing and a $0.6 million rise in other research and preclinical costs were partly offset by a $1.6 million decrease in FASCINATE-2 trial costs after patient dosing was completed in 2023.
- G&A rose $1.2 million, or 54%. Higher interest income largely offset the increase in operating expenses, leaving net loss nearly unchanged.
- Q1 2024 financing included a follow-on sale of 9.0 million Series A shares at $12.50 per share; the filing reports net proceeds of approximately $104.7 million. Series A shares outstanding rose to 30.4 million from 21.4 million at year-end.
- Per-share loss figures are not directly comparable: weighted-average shares were 29.0 million in Q1 2024 versus 185,137 in Q1 2023, following the IPO and share conversion. The filing also reflects a 1-for-79.4784 reverse stock split.
Outlook, development and risks
- In January 2024, the company reported positive topline Phase 2b FASCINATE-2 results for denifanstat in MASH patients with F2/F3 fibrosis. Reported week-52 results included MASH resolution without worsening fibrosis of 36% versus 13% for placebo, and fibrosis improvement without worsening MASH of 41% versus 18%.
- The company is designing a pivotal Phase 3 MASH program and plans to initiate it in the second half of 2024, after an expected FDA End-of-Phase 2 meeting in Q2 2024. These are plans, not guaranteed outcomes.
- License partner Ascletis is conducting Phase 3 trials in China for moderate-to-severe acne and recurrent glioblastoma in combination with bevacizumab. Sagimet has completed IND-enabling studies for its second candidate, TVB-3567.
- Management expects expenses to increase as development advances. The company depends on third parties for clinical trials, manufacturing and supply; delays, safety or efficacy findings, regulatory requirements, competition, and difficulty obtaining future financing could affect programs and liquidity. Additional capital may be required, potentially diluting shareholders or imposing debt restrictions.
- No material legal proceedings or material changes to previously disclosed risk factors were reported. The headquarters lease was extended through June 30, 2025, with monthly payments increasing to approximately $13,000 beginning July 2024.
Important facts for investors to verify
- Whether FDA feedback and trial design support the stated Phase 3 start timing and what the trial will cost.
- Whether the Phase 2b efficacy findings are confirmed in further studies and the full safety and durability data.
- Cash burn, investment balances and financing needs relative to the stated 12-month-plus runway.
- Follow-on offering proceeds, share-count changes and potential dilution from outstanding options and restricted stock units.
- Progress and results of Ascletis’s China trials, and the terms and potential economics of the license agreement.